EP0471790A4 - Method for localization and treatment of tumors and complexes therefor - Google Patents

Method for localization and treatment of tumors and complexes therefor

Info

Publication number
EP0471790A4
EP0471790A4 EP19900908791 EP90908791A EP0471790A4 EP 0471790 A4 EP0471790 A4 EP 0471790A4 EP 19900908791 EP19900908791 EP 19900908791 EP 90908791 A EP90908791 A EP 90908791A EP 0471790 A4 EP0471790 A4 EP 0471790A4
Authority
EP
European Patent Office
Prior art keywords
localization
tumors
treatment
complexes
therefor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19900908791
Other versions
EP0471790A1 (en
Inventor
Steven Kornguth
Patrick Turski
H. Ian Robins
Robert J. Nickles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of EP0471790A1 publication Critical patent/EP0471790A1/en
Publication of EP0471790A4 publication Critical patent/EP0471790A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
EP19900908791 1989-05-04 1990-05-02 Method for localization and treatment of tumors and complexes therefor Withdrawn EP0471790A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34735889A 1989-05-04 1989-05-04
US347358 1989-05-04

Publications (2)

Publication Number Publication Date
EP0471790A1 EP0471790A1 (en) 1992-02-26
EP0471790A4 true EP0471790A4 (en) 1992-07-08

Family

ID=23363373

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900908791 Withdrawn EP0471790A4 (en) 1989-05-04 1990-05-02 Method for localization and treatment of tumors and complexes therefor

Country Status (5)

Country Link
EP (1) EP0471790A4 (en)
AU (1) AU628988B2 (en)
CA (1) CA2032169A1 (en)
FR (1) FR2646608A1 (en)
WO (1) WO1990013256A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
DE102007059752A1 (en) * 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Functionalized solid polymer nanoparticles containing epothilones
EP2277547A1 (en) * 2009-07-20 2011-01-26 Merck Patent GmbH Epsilon-polylysine conjugates and their utilisation
GB201106742D0 (en) * 2011-04-20 2011-06-01 Spheritech Ltd Cross-linked poly-e-lysine
WO2013138696A1 (en) * 2012-03-16 2013-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zirconium-89 complexes, methods of labeling cells, labeled cells, kits, and methods of use thereof
GB2562004B (en) * 2012-04-20 2019-10-23 Spheritech Ltd Cross-linked poly-e-lysine particles
CA3045466A1 (en) 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
JPH01176000A (en) * 1987-12-30 1989-07-12 Nippon Mejifuijitsukusu Kk Radioactive medicine and polymer compound for preparing said medicine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4731239A (en) * 1983-01-10 1988-03-15 Gordon Robert T Method for enhancing NMR imaging; and diagnostic use
US4687659A (en) * 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
US4639365A (en) * 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
DK172629B1 (en) * 1986-02-14 1999-03-22 Nihon Mediphysics Co Ltd Reactive high molecular weight compounds with at least one free amino group, high molecular weight compounds combined with a physiological
AU629171B2 (en) * 1987-06-30 1992-10-01 Mallinckrodt, Inc. Method for enhancing the safety of metal-ligand chelates as magnetic resonants imaging agents and x-ray contrast agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
JPH01176000A (en) * 1987-12-30 1989-07-12 Nippon Mejifuijitsukusu Kk Radioactive medicine and polymer compound for preparing said medicine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MOLECULAR PHARMACOLOGY, vol. 27, 1984, pages 141-147, The American Society for Pharmacology and Experimental Therapeutics; A. ROSOWSKY et al.: "Regiospecific gamma-conjugation of methotrexate to poly(L-lysine)" *
See also references of WO9013256A1 *
SERVEUR STN, BASE DE DONNEES, CHEMICAL ABSTRACTS, vol. 112, no. 23, abstract no. 213185g, Columbus, Ohio, US; & JP-A-1 176 000 (NIHON MEDI-PHYSICS CO., LTD) 12-07-1989 *
SERVEUR STN, BASE DE DONNEES, CHEMICAL ABSTRACTS, vol. 112, no. 7, abstract no. 51378t, Columbus, Ohio, US; S.E. KORNGUTH et al.: "Preferential binding of radiolabeled poly-L-lysines to C6 and U87 MG glioblastomas compared with endothelial cells in vitro", & CANCER RES., 49(22), 6390-5 *

Also Published As

Publication number Publication date
WO1990013256A1 (en) 1990-11-15
FR2646608A1 (en) 1990-11-09
AU5679490A (en) 1990-11-29
CA2032169A1 (en) 1990-11-05
AU628988B2 (en) 1992-09-24
EP0471790A1 (en) 1992-02-26

Similar Documents

Publication Publication Date Title
AU6592390A (en) Method and apparatus for the treatment of cancer
GB2188238B (en) Apparatus for magnetic therapy
AU7223391A (en) Apparatus for hyperthermia treatment of cancer
EP0471790A4 (en) Method for localization and treatment of tumors and complexes therefor
GB9010058D0 (en) Method and composition for the treatment of cancer
AU639371B2 (en) Method of treating breast cancer
GB8916394D0 (en) Method of treatment
ZA932731B (en) Method of treating gar-transformylase-dependent tumors
IL87496A0 (en) Apparatus and method for diagnosis of breast cancer
GB8802407D0 (en) Apparatus & method for diagnosis of malignant tumours
GB8908539D0 (en) Treatment of cancer
GB8906425D0 (en) Method of treatment
GB8912934D0 (en) Method of treatment
GB8912935D0 (en) Method of treatment
GB8906424D0 (en) Method of treatment
GB8911258D0 (en) Method of treatment
GB8906430D0 (en) Method of treatment
GB8906429D0 (en) Method of treatment
GB8906428D0 (en) Method of treatment
GB8906427D0 (en) Method of treatment
GB8906426D0 (en) Method of treatment
GB8924155D0 (en) Method of treatment
GB8904258D0 (en) Method of treatment
GB8920985D0 (en) Method of treatment
GB8929033D0 (en) Method of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910123

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19920521

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920827